Indinavir and Rifabutin Drug Interactions in Healthy Volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 3, 2004, Pages 305-313

  Kraft, Walter K ^a   McCrea, Jacqueline B ^b   Winchell, Gregory A ^b   Carides, Alexandra ^b   Lowry, Richard ^b   Woolf, Eric J ^b   Kusma, Sandra E ^b   Deutsch, Paul J ^b   Greenberg, Howard E ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiretrovirals; Drug interactions; HIV; Indinavir; Pharmacokinetics; Rifabutin

Indexed keywords

CYTOCHROME P450 3A4; INDINAVIR; RIFABUTIN;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; MALE; MONOTHERAPY; NORMAL HUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; INDINAVIR; MALE; METABOLIC CLEARANCE RATE; RIFABUTIN; TIME FACTORS;

EID: 10744233066     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003262807     Document Type: Article

References (23)

1. Peng C, Ho BK, Chang TW, Chang NT: Role of human immunodeficiency virus type 1-specific protease in core maturation and viral infectivity. J Virol 1989;63:2550-2556.
2. Kaul DR, Cinti SK, Carver PL, Kazanjian PH: HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999;19:281-298.
3. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
4. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
5. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW, and the Adult/Adolescent Spectrum of Disease Group: Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 1999;13:1687-1695.
6. Masur H, Kaplan JE, Holmes KK: Guidelines for preventing opportunistic infections among HIV-infected persons-2002: recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002;137:435-478.
7. Benson C, Williams P, Currier J, Holland F, Hojczyk P, Mahon L, et al: ACTG 223: an open, prospective, randomized study comparing efficacy and safety of clarithromycin plus ethambutol, rifabutin, or both for treatment of MAC disease in patients with AIDS [abstract 249]. Paper presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
8. Centers for Disease Control and Prevention: Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47:RR-20.
9. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996;24:307-314.
10. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, et al: Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chemico-Biological Interact 1997;107:17-30.
11. Blaschke TF, Skinner MH: The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996;22(Suppl. 1):S15-S22.
12. Woolf E, Haddix Au H, Matuszewski B: Determination of L-753 524, a human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatograph with column switching. J Chromatogr 1995;692:45-52.
13. Yeh KC, Small RD: Pharmacokinetic evaluation of stable piecewise cubic polynomials as numerical integration functions. J Pharmacokinet Biopharm 1989;17:721-740.
14. Ciminera JL, Bolognese JA, Gregg MH: The statistical evaluation of a three-period two-treatment crossover pharmacokinetic drug interaction study. Biometrics 1987;43:713-718.
15. Tomasko L, Bolognese JA, Hesney M, Holder DJ: Comparison of two modeling procedures for the three-period, two-treatment crossover pharmacokinetic drug interaction study [abstract]. Paper presented at the 17th International Biometric Conference, Hamilton, Canada, August 8-12, 1994.
16. Merck and Co.: Crixivan (indinavir) package insert. West Point, PA, March 1999.
17. Dautzenberg B: The use of rifabutin in Europe for the treatment of mycobacterial infection in AIDS patients. Infection 1997;25:63-68.
18. Cocchiara G, Benedetti MS, Vicario GP, Ballabio M, Gioia B, Vioglio S, et al: Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 1989;19:7869-7880.
19. Mascolini M: The rolling uncertainties of antiprotease prescribing. J Int Assoc Physicians AIDS Care 1996;2:6-10.
20. Clumeck N: Choosing the best initial therapy for HIV-1 infection. N Engl J Med 1999;341:1925-1926.
21. Flexner C, Barditch-Crovo PA: Severe neutropenia among healthy volunteers given rifabutin in clinical trials [letter]. Clin Pharmacol Ther 2003;73:159-169.
22. Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, et al: Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 2003;73:159-169.
23. Panel on Clinical Practices for Treatment of HIV Infection: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available: http://aidsinfo.nih.gov/guidelines/adult/AA_020402.html#table18